MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Supernus Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

32.83 4.06

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

31.13

Максимум

32.89

Ключови измерители

By Trading Economics

Приходи

-23M

15M

Продажби

-1.5M

174M

P/E

Средно за сектора

24.811

63.778

EPS

0.548

Марж на печалбата

8.801

Служители

674

EBITDA

-20M

45M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+22.47% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-272M

1.8B

Предишно отваряне

28.77

Предишно затваряне

32.83

Настроения в новините

By Acuity

16%

84%

28 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Supernus Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.04.2024 г., 18:04 ч. UTC

Значими двигатели на пазара

Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready

Сравнение с други в отрасъла

Ценова промяна

Supernus Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

22.47% нагоре

12-месечна прогноза

Среден 38.8 USD  22.47%

Висок 44 USD

Нисък 36 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Supernus Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

2

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

31.63 / 32.28Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

28 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.